摘要
目的探讨血清肿瘤标志物CA19-9、CA242、CA125、CEA检测在胰腺癌诊断及疗效监测的价值。方法用多肿瘤标志物蛋白芯片诊断系统测定87例胰腺炎患者、1150例健康体检者(对照组)1、33例胰腺癌患者,及30例胰腺癌患者手术前后血清中CA199、CA242、CA125、CEA含量。结果肿瘤标志物CA199、CA242、CA125、CEA胰腺癌组的阳性率为84.9%,炎症组阳性率为38.7%,正常对照组阳性率为1.6%,胰腺癌组阳性率显著高于胰腺炎组和健康体检对照组(P<0.01)。胰腺癌患者手术前4项肿瘤标志物的水平表达高于手术后(P<0.05)。结论联合检测血清CA199、CA242、CA125、CEA水平对胰腺癌辅助诊断有较好的临床参考价值。
Objective To discuss the diagnostic and therapeutic effect monitoring value of detecting serum tumor marker,CA19-9,CA242,CA125,CEA in pancreatic cancer.Methods CA19-9,CA242,CA125,CEA of 133 patients of pancreatic cancer,30 cases of preoperation and postoperation,87 pancreatitis are detected by Multi-Tumor Markers Protein Biochip Diagnosis System,1150 health examinates as the control group.Results The positive ratio of pancreatic cancer group is 84.9%,much more than it of pancreatitis（38.7%） and health examinates（1.6%）,P0.01.The concentrations of the four markers in the cases of preoperation are higher than that of postoperation,P0.05.Conclusion Detecting serum tumor marker,CA19-9,CA242,CA125,CEA simultaneously has better clinical value in auxiliary diagnosis of pancreatic cancer.
出处
《中国实验诊断学》
北大核心
2011年第7期1087-1088,共2页
Chinese Journal of Laboratory Diagnosis
关键词
胰腺癌
肿瘤标志物
Pancreatic Cancer
Tumor Marker
